Brokerages predict that ANCHIANO THERAP/S (NASDAQ:ANCN) will post earnings of ($0.13) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ANCHIANO THERAP/S’s earnings. The business is scheduled to report its next quarterly earnings results on Monday, March 23rd.
On average, analysts expect that ANCHIANO THERAP/S will report full year earnings of ($1.33) per share for the current fiscal year, with EPS estimates ranging from ($1.46) to ($1.19). For the next financial year, analysts expect that the firm will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.51) to ($0.45). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for ANCHIANO THERAP/S.
A number of equities research analysts recently weighed in on the company. Oppenheimer cut ANCHIANO THERAP/S from an “outperform” rating to a “market perform” rating and set a $16.00 price target on the stock. in a research note on Monday, November 18th. Zacks Investment Research cut shares of ANCHIANO THERAP/S from a “buy” rating to a “hold” rating in a research report on Tuesday, October 8th. LADENBURG THALM/SH SH downgraded shares of ANCHIANO THERAP/S from a “buy” rating to a “neutral” rating in a report on Monday, November 18th. Finally, Robert W. Baird lowered shares of ANCHIANO THERAP/S from an “outperform” rating to a “neutral” rating in a research report on Monday, November 18th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $10.42.
A number of hedge funds have recently modified their holdings of ANCN. FMR LLC acquired a new stake in ANCHIANO THERAP/S during the first quarter worth approximately $288,000. Virtu Financial LLC bought a new stake in shares of ANCHIANO THERAP/S during the third quarter worth approximately $30,000. Finally, Phoenix Holdings Ltd. bought a new stake in shares of ANCHIANO THERAP/S during the third quarter worth approximately $57,000. Hedge funds and other institutional investors own 13.29% of the company’s stock.
Shares of ANCN stock traded down $0.02 during trading on Friday, reaching $1.59. 5,220 shares of the company’s stock were exchanged, compared to its average volume of 23,250. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $11.79 million and a PE ratio of -0.30. ANCHIANO THERAP/S has a twelve month low of $1.24 and a twelve month high of $11.50. The firm’s fifty day moving average price is $1.95 and its 200-day moving average price is $3.07.
ANCHIANO THERAP/S Company Profile
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.
Featured Article: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.